The ratio between pro and anti-apoptotic BCL-2 family members determines cellular sensitivity to death-inducing signals, including chemotherapeutic agents; around 50% of AML have increased BCL-2 expression, which correlates with poor prognosis [5,6]. This evidence concerns the gene BCL2 and acute myeloid leukemia.